Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Casanova MJ
  • Rubín de Célix C
  • Riestra S
  • Lucendo AJ
  • Benítez JM
  • Navarro-Llavat M
  • Barrio J
  • Morales-Alvarado VJ
  • Rivero M
  • Busquets D
  • Leo-Carnerero E
  • Nantes-Castillejo O
  • Navarro P
  • Van Domselaar M
  • Gutiérrez-Casbas A
  • Alonso-Abreu I
  • Barreiro-de Acosta M
  • Fernández-Salazar L
  • Martín-Arranz MD
  • García-Morales N
  • Guardiola J
  • Bouhmidi-Assakali A
  • Esteve M
  • Muñoz-Villafranca C
  • Rodríguez-Lago I
  • Ceballos D
  • Guerra I
  • Mañosa M
  • Marín-Jiménez I
  • Vera-Mendoza I
  • Garre A
  • Chaparro M
  • Gisbert JP
  • EXIT long-term study group of GETECCU

Grupos

Abstract

BACKGROUND: The EXIT trial found no difference in sustained remission at 12 months between inflammatory bowel disease (IBD) patients in remission who withdrew anti-TNF therapy [withdrawal arm (WA)] and those who maintained treatment [maintenance arm (MA)]. AIMS: To compare the long-term risk of relapse between these groups and assess the response to anti-TNF resumption. METHODS: This was a follow-up extension of the EXIT trial. We analysed long-term outcomes of patients in sustained clinical remission from the start of EXIT. RESULTS: We included 125 patients (63 in MA and 62 in WA). Median follow-up was 12 months for MA and 26 months for WA. The cumulative incidence of relapse (95% CI) was 35% (23%-48%) in MA and 47% (34%-60%) in WA; p = 0.3. In MA, relapses occurred in 8% of patients by 12 months and 47% by 24 months. In WA, relapses occurred in 16% by 12 months and 39% by 24 months. The incidence rate of relapse per patient-year was 22% in MA and 19% in WA. Baseline faecal calprotectin > 250 µg/g was the only variable associated with a higher risk of relapse. Of the 29 patients who relapsed in WA, 26 (90%) resumed anti-TNF therapy; of these, 69% regained clinical remission. CONCLUSION: In this extended analysis of patients included in the EXIT trial, withdrawing anti-TNF therapy in patients with IBD in remission was not associated with a higher long-term relapse risk.

© 2025 John Wiley & Sons Ltd.

Datos de la publicación

ISSN/ISSNe:
0269-2813, 1365-2036

ALIMENTARY PHARMACOLOGY & THERAPEUTICS  WILEY

Tipo:
Article
Páginas:
59-71
PubMed:
40317957
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
2,850 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 5

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Crohn's disease; anti-TNF; inflammatory bowel disease; maintenance; ulcerative colitis

Cita

Compartir